Hereditary nonpolyposis colon cancer: Revised Bethesda criteria, immunohistochemistry, microsatellite instability, germline analysis, and emerging issues in genetic testing

Current Colorectal Cancer Reports

Volumn 3, Issue 1, 2007, Pages 10-15

  Doxey, Brett W ^b   Kuwada, Scott K ^a  

^a UNIVERSITY OF UTAH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953100469     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-007-0010-x     Document Type: Review

References (67)

1. Wijen J, Khan PM, Vasen H, et al.: Hereditary nonpol-yposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch repair gene mutations. Am J Hum Genet 1997, 61:329-335.
2. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al.: A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997, 89:1758-1762.
3. Umar A, Boland CR, Terdiman JP, et al.: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-268.
4. Wolf B, Gruber S, Henglmueller S, et al.: Effciency of the revised Bethesda guidelines (2003) for the detection of mutations in mismatch repair genes in HNPCC patients. Int J Cancer 2006, 118:1465-1470.
5. Rodríguez-Moranta F, Castells A, Andreu M, et al.: Clinical performance of original and revised Bethesda guidelines for the identifcation of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol 2006, 101:1104-1111.
6. Piñol V, Castells A, Andreu M, et al.: Accuracy of revised Bethesda guidelines, microsatellite instability, and immu-nohistochemistry for the identifcation of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005, 293:1986-1994.
7. Peltomaki P, Vasen H: Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroen-terology 1997, 113:1146-1158.
8. Bronner CE, Baker SM, Morrison PT, et al.: Mutation in the DNA mismatch repair gene homologue hMHLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994, 368:258-261.
9. Fishel R, Lescoe MK, Rao M, et al.: The human mutator gene homolog MSH2 and its association with hereditary non-polyposis colorectal cancer. Cell 1993, 75:1027-1038.
10. Jiricny J: Mediating mismatch repair. Nat Genet 2000, 24:6-8.
11. Peltomaki P, Vasen HF, et al.: Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997, 113:1146-1158.
12. Lynch HT, Lynch J: Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J Clin Oncol 2000, 18:19S-31S.
13. Berends MJ, Wu Y, Sijmons RH, et al.: Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 2002, 70:26-37.
14. Lawes DA, SenGupta SB, Boulos PB: Pathogenesis and clinical management of hereditary nonpolyposis colorectal cancer. Br J Surg 2002, 89:1357-1369.
15. Nicolaides NC, Papadopoulos N, Liu B, et al.: Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994, 371:75-80.
16. Kiu B, Parsons R, Papadopoulos N, et al.: Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996, 2:169-174.
17. Wang Q, Lasset C, Desseigne F, et al.: Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer. Hum Genet 1999, 105:79-85.
18. Watanabe A, Ikejima M, Suzuki N, et al.: Genomic organization and expression of the human MSH3 gene. Genomics 1996, 31:311-318.
19. De Rosa M, Fasano C, Panariello L, et al.: Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene. Oncogene 2000, 19:1719-1723.
20. Miyaki M, Nishio M, Kikuchi-Yanoshita R, et al.: Drastic genetic instability of tumors and normal tissues in Turcot syndrome. Oncogene 1997, 15:2877-2881.
21. Liu T, Yan H, Kuismanen S, et al.: The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. Cancer Res 2001, 61:7798-7802.
22. Wu Y, Berends M, Post J, et al.: Germline mutations EX01 gene patients with hereditary nonpolyposis colorectal cancer (HNPCC) atypical HNPCC forms. Gastroenterol-ogy 2001, 120:1580-1587.
23. Thompson E, Meldrum CJ, Crooks R, et al.: Hereditary non-polyposis colorectal cancer and the role of hPMS2 and hEX01 mutations. Clin Genet 2004, 65:215-255.
24. Truninger K, Menigatti M, Luz J, et al.: Immunohisto-chemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005, 128:1160-1171.
25. Baudhuin LM, Mai M, French AJ, et al.: Analysis of hMLH1 and hmSH2 gene dosage alterations in hereditary nonpolyposis colorectal cancer patients by novel methods. J Mol Diagn 2005, 7: 226-235.
26. Nakagawa H, Lockman JC, Frankel WL, et al.: Mismatch repair gene PMSH2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMSH2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res. 2004, 64:4721-4727.
27. Miyaki M, Konishi M, Tanaka K, et al.: Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997, 17:271-272.
28. Wu Y, Berends MJ, Mensink RG, et al.: Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 1999, 65:1291-1298.
29. Plaschke J, Engel C, Kruger S, et al.: Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 2004, 22:4486-4494.
30. Kolodner R, Tytell JD, Schmeits JL, et al.: Germline MSH6 mutations in colorectal cancer families. Cancer Res 1999, 59:5068-5074.
31. Wijnen J, de Leeuw W, Vasen H, et al.: Familial endome-trial cancer in female carriers of MSH6 germline mutations. Nat Gen 1999, 23:142-144.
32. Akiyama Y, Sato H, Yamada T, et al.: Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997, 57:3920-3923.
33. Charbonnier F, Olschwang S, Wang Q, et al.: MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpol-yposis colorectal cancer. Cancer Res 2002, 62:848-853.
34. Wagner A, Barrows A, Wijnen JT, et al.: Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 2003, 72:1088-1100.
35. Wang Y, Friedl W, Lamberti C, et al.: Hereditary non-polyposis colorectal cancer: frequent occurrence of large genomic deletions in MSH2 and MLH1 genes. Int J Cancer 2003, 103:636-641.
36. Baudhuin LM, Ferber MJ, Winters JL, et al.: Characterization of hMLH1 and hMSHS2 gene dosage alterations in Lynch syndrome patients. Gastroenterology 2005, 129:846-854.
37. Grabowski M, Mueller-Koch Y, Grasbon-Frodl E, et al.: Deletions account for 17% of pathogenic germline alterations in MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer (HNPCC) families. Genet Test 2005, 9:138-146.
38. Mangold E, Pagenstecher C, Friedl W, et al.: Spectrum and frequencies of mutations in MSH2 and MLH1 identifed in 1721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer 2005, 116: 692-702.
39. Giardiello FM, Brensinger JD, Petersen GM: AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001, 121:198.
40. Boland CR, Thibodeau SN, Hamilton SR, et al.: A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-5257.
41. Aaltonen LA, Peltomaki P, Leach FS, et al.: Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260:812-816.
42. Ionov Y, Peinado MA, Malkhosyan S, et al.: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993, 363:558-561.
43. Loukola A, de la Chapelle A, Aaltonen LA: Strategies for screening for hereditary non-polyposis colorectal cancer. J Med Genet 1999, 36:819-822.
44. Aaltonen LA, Salovaara R, Kristo P, et al.: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998, 21:1481-1487.
45. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor mic ro-satellite- instability status as a predictor of beneft from fuorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
46. Southey MC, Jenkins MA, Mead L, et al.: Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005, 23:6524-6532.
47. Kievit W, de Bruin JH, Adang EM, et al.: Current clinical selection strategies for identifcation of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clin Genet 2004, 65:308-316.
48. Lynch HT, Riley BD, Weissman SM: Hereditary nonpol-yposis colorectal carcinoma (HNPCC) and HNPCC-like families: problems in diagnosis, surveillance, and management. Cancer 2004, 100:53-64.
49. de la Chapelle A: Microsatellite instability phenotype of tumors: genotyping or immunohistochemistry? The jury is still out. J Clin Oncol 2002, 20:897-899.
50. Hampel H, Frankel WL, Martin E, et al.: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005, 352:1851-1860.
51. Baudhuin LM, Burgart LJ, Leontovich O, et al.: Use of microsatellite instability and immunohistochemistry testing for the identifcation of individuals at risk for Lynch syndrome. Fam Cancer 2005, 4:255-265.
52. Engel C, Forberg J, Holinski-Feder E, et al.: Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 2006, 118:115-122.
53. Cunningham JM, Kim CY, Christensen ER, et al.: The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001, 69:780-790.
54. Yuen ST, Chan TL, Ho JW, et al.: Germline somatic and epigenetic events underlying mismatch repair defciency in colorectal and HNPCC-related cancers. Oncogene 2002, 21:7585-7592.
55. Raedle J, Trojan J, Brieger A, et al.: Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. Ann Intern Med 2001, 135:566-576.
56. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
57. Sommerer F, Vieth M, Markwarth A, et al.: Mutations of BRAF and KRAS2 in the development of Barrett's adeno-carcinoma. Oncogene 2004, 23:554-558.
58. Yuen ST, Davies H, Chan TL, et al.: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002, 62:6451-6455.
59. Chan TL, Wei Z, Suet LY, Siu YT: BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 2003, 63:4878-4881.
60. Rajagopalan H, Bardelli A, Lengauer C, et al.: Tu mori-genesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
61. Aaltonen LA, Peltomaki P, Mecklin JP, et al.: Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994, 54:1645-1648.
62. Domingo E, Espin E, Armengol M, et al.: Activated BRAF targets proximal colon tumors with mismatch repair defciency and MLH1 inactivation. Genes Chromosomes Cancer 2004, 39:138-142.
63. Deng G, Bell I, Crawley S, et al.: BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004, 10:191-195.
64. Domingo E, Niessen RC, Oliveira C, et al.: BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Onco-gene 2005, 24:3995-3998.
65. Domingo E, Laiho P, Ollikainen M, et al.: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004, 41: 664-668.
66. Wang L, Cunningham JM, Winters JL, et al.: BRAF mutations in colon cancer are not likely attributed to defective DNA mismatch repair. Cancer Res 2003, 63:5209-5212.
67. Cao Y, Oieretti M, Marshall J, et al.: Challenges in the differentiation between attenuated familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer: case report with review of the literature. Am J Gastroen-terol 2002, 97:1822-1827.